Skip to main content

Sylatron FDA Approval History

FDA Approved: Yes (First approved March 29, 2011)
Brand name: Sylatron
Generic name: peginterferon alfa-2b
Company: Merck
Treatment for: Melanoma

Sylatron (peginterferon alfa-2b) is an alpha interferon indicated for the adjuvant treatment of melanoma.

Development timeline for Sylatron

Apr 12, 2011Approval FDA Approves Merck's Sylatron (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.